<DOC>
	<DOCNO>NCT00509548</DOCNO>
	<brief_summary>Wet age-related macular degeneration ( AMD ) cause formation growth abnormal blood vessel ( angiogenesis ) retina . The new blood vessel fragile wall leak fluid retina . The build-up fluid ( edema ) macula distort vision cause vision loss . TG100801 topical ( eye drop ) therapy show inhibit ocular angiogenesis , vascular leak , inflammation laboratory study . The primary purpose pilot study evaluate ability topical administration TG100801 reduce amount fluid retina patient AMD follow 30 day treatment . An additional objective evaluate safety TG100801 patient AMD .</brief_summary>
	<brief_title>Open-Label , Pilot Study TG100801 Patients With Choroidal Neovascularization Due AMD</brief_title>
	<detailed_description>Choroidal neovascularization ( CNV ) due AMD lead cause irreversible , severe vision loss people 55 year old develop world . TG100801 potent inhibitor vascular growth endothelial factor ( VEGF ) kinases contribute CNV macular edema . Animal model demonstrate ability TG100801 inhibit angiogenesis , vascular leak , inflammation . TG100801 develop topical ( eye drop ) therapy treatment CNV due AMD . The primary objective multicenter , open-label , randomize , pilot study evaluate effect 30 day dose two dose level TG100801 central retinal/lesion thickness , measure optical coherence tomography ( OCT ) . The safety TG100801 patient AMD also evaluate .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<criteria>Subfoveal CNV secondary AMD study eye CNV lesion size le equal 12 MPS disk area CNV &gt; 50 % lesion area Presence intraretinal fluid cause increase central subfield thickness least 250 micron , confirm OCT study eye Any lesion composition Best correct visual acuity 20/40 20/320 ( 73 24 ETDRS letter ) 4 meter study eye Best correct visual acuity 20/800 better ( least 4 ETDRS letter ) 4 meter fellow eye Ability administer tolerate eye drop Able give write informed consent History treatment subfoveal CNV study eye Known anticipate need use topical medication study eye 30day dosing period Current anticipate need available ocular antiVEGF therapy fellow eye 30 day prior 30 day follow baseline RPE rip tear study eye Blood &gt; 1 disk area , atrophy , fibrosis ( disciform scar ) foveal center study eye Scarring/fibrosis least 25 % total CNV lesion study eye Hemorrhage PED &gt; 50 % total CNV lesion study eye Glaucoma visual field loss IOP least 25 mmHg study eye consistently least 25 mmHg fellow eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>